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OBJECTIVES The purpose of this study was to assess whether metabolic syndrome (MetSyn) predicts a
higher risk for cardiovascular events in older adults.
BACKGROUND The importance of MetSyn as a risk factor has not previously focused on older adults and
deserves further study.
METHODS We studied the impact of MetSyn (38% prevalence) on outcomes in 3,035 participants in the
Health, Aging, and Body Composition (Health ABC) study (51% women, 42% black, ages
70 to 79 years).
RESULTS During a 6-year follow-up, there were 434 deaths overall, 472 coronary events (CE), 213
myocardial infarctions (MI), and 231 heart failure (HF) hospital stays; 59% of the subjects
had at least one hospital stay. Coronary events, MI, HF, and overall hospital stays occurred
significantly more in subjects with MetSyn (19.9% vs. 12.9% for CE, 9.1% vs. 5.7% for MI, 10.0%
vs. 6.1% for HF, and 63.1% vs. 56.1% for overall hospital stay; all p  0.001). No significant
differences in overall mortality was seen; however, there was a trend toward higher cardiovascular
mortality (5.1% vs. 3.8%, p 0.067) and coronary mortality (4.5% vs. 3.2%, p 0.051) in patients
with MetSyn. After adjusting for baseline characteristics, patients with MetSyn were at a
significantly higher risk for CE (hazard ratio [HR] 1.56, 95% confidence interval [CI] 1.28 to
1.91), MI (HR 1.51, 95% CI 1.12 to 2.05), and HF hospital stay (HR 1.49, 95% CI 1.10 to 2.00).
Women and whites with MetSyn had a higher coronary mortality rate. The CE rate was higher
among subjects with diabetes and with MetSyn; those with both had the highest risk.
CONCLUSIONS Overall, subjects over 70 years are at high risk for cardiovascular events; MetSyn in this group
is associated with a significantly greater risk. (J Am Coll Cardiol 2006;47:1595–602)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.046© 2006 by the American College of Cardiology Foundation
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betabolic syndrome (MetSyn) has recently been acknowl-
dged as a risk factor for cardiovascular disease and mortal-
ty (1–4). The third report of the National Cholesterol
ducation Program Expert Panel on Detection, Evaluation,
nd Treatment of High Blood Cholesterol in Adults (ATP
II) specifically underscores the importance of the MetSyn
nd provides a working definition of this syndrome (5).
indings from the third National Health and Nutrition
xamination Survey showed that the MetSyn is highly
revalent within the U.S. (6); however, most of the data
egarding MetSyn and cardiovascular outcomes are derived
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ute of Aging, National Institutes of Health, Bethesda, Maryland; and the Clinical
utrition Research Unit, Vanderbilt University; and in part by Grant NIH-DK26657-24.o
Manuscript received August 24, 2005; revised manuscript received December 1,
005, accepted December 5, 2005.rom populations consisting mostly of middle-aged and
ounger subjects. Although elderly subjects might have been
ncluded in some of these studies, to date there are no large
tudies that have primarily focused on MetSyn in the elderly
opulation exclusively. Therefore, whether MetSyn is as
trong a cardiovascular risk factor in older adults as it is in
ounger populations has not been established. Some differ-
nces in the risk factors and their importance among the
eriatric versus the broader adult patient population have
een described previously, and the predictive power of many
raditional cardiovascular risk factors diminishes with in-
reasing age (7–9). This is an important issue, because the
roportion of older adults in the population is increasing
nd the trend is projected to continue (10). This becomes
ven more important when considering that older adults are
ot treated as aggressively as younger subjects (11–13).
The Health, Aging, and Body Composition Study (Health
BC) was designed to investigate the impact of changes in
ody composition and health conditions on age-related phys-
ological and functional status among adults from 70 to 79
ears of age. In this cohort, we assessed the relationship
etween MetSyn, cardiovascular outcomes, and mortality in
lder adults.
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tudy populations. Study subjects for this investigation in-
luded participants in the Health ABC study, a population-
ased cohort of 3,075 healthy, well-functioning, community-
welling men and women ages 70 to 79 years. To be eligible
or participation in Health ABC study, subjects had to report
o difficulty in walking one-quarter mile or climbing 10
tairs without resting. Participants were identified from a
andom sample of white Medicare beneficiaries and all
ge-eligible black community residents in designated zip
ode areas surrounding Pittsburgh and Memphis. Exclusion
riteria included: difficulties with activities of daily living,
bvious cognitive impairment, inability to communicate
ith the interviewer, intention of moving within three years,
r participation in a trial involving a lifestyle intervention.
ll participants gave written informed consent: the institu-
ional review boards at both study sites approved the
rotocol. Forty subjects from this cohort were excluded,
wing to missing data needed to define MetSyn; thus a total
f 3,035 subjects were studied. Baseline data were collected
n 1997 to 1998, and these results represent the outcomes
uring the first six years of follow-up.
tudy definitions. Subjects were classified with the base-
ine data into those who did and did not have MetSyn, using
he ATP III guidelines (any three of the following risk
actors: increased waist circumference [men 101.6 cm and
omen 88.9 cm], triglycerides 150 mg/dl, low high-
ensity lipoprotein cholesterol [men 40 mg/dl, women 50
g/dl], blood pressure 130/85 mm Hg, and fasting glu-
ose 110 mg/dl) (5). Diabetes was defined in Health ABC
tudy as self-reported diagnosis and/or as using any anti-
yperglycemic medication at baseline. Participants taking
nti-hyperglycemic medications were counted as meeting
he glucose criterion, and participants taking antihyperten-
ive medication were counted as meeting the blood pressure
riterion. Smoking status was defined as current, past use (if
he participant had stopped smoking, but smoked at least
00 cigarettes in his/her life), or never.
tudy outcomes. Participants were asked to report any
ospital stays, and every 6 months they were asked direct
uestions to elicit information about interim cardiovascular
vent. When an event was reported, hospital stay records
ere collected and the diagnosis was verified by a Health
Abbreviations and Acronyms
CE  coronary event
CHD  coronary heart disease
CI  confidence interval
Health ABC  Health, Aging, and Body Composition
study
HF  heart failure
HR  hazard ratio
MetSyn  metabolic syndrome
MI  myocardial infarctionBC Disease Adjudication Committee, and only confirmed rvents were included. Coronary event (CE) was defined as
dmission to the hospital for myocardial infarction (MI),
ngina, or either percutaneous or surgical revascularization.
yocardial infarction was defined by coronary death or any
vernight hospital stay for acute MI. Similarly, all hospital
dmissions that were confirmed as related to decompensated
eart failure (HF) were studied. Events and diagnoses were
djudicated on the basis of hospital stay records and death
ecords. Date of death was taken from the death certificate
nd hospital stay records. Underlying causes of death were
etermined by central adjudication. Coronary heart death
as defined as any death where the underlying cause of
eath was ascertained as atherosclerotic cardiovascular dis-
ase, which included definite fatal MI, definite fatal coro-
ary heart disease (CHD), and possible fatal CHD. Car-
iovascular death was defined as any death classified as
oronary death or death due to HF.
tatistical analyses. Descriptive and exploratory analyses
ere used to evaluate demographic characteristics stratified
y MetSyn status at baseline. Bivariate analyses were per-
ormed to assess the associations between MetSyn and risk
or MI, HF hospital stay, CE, overall hospital stay, and
oronary, cardiovascular, and overall mortality, stratified by
ace and gender. Furthermore, a sub-group analysis of 2,249
atients without any past history of CHD or HF was
onstructed to assess the importance of MetSyn in predict-
ng new onset events. For this analysis, we excluded partic-
pants with baseline cardiovascular disease, defined as CHD
angina, MI, angioplasty of coronary arteries, or coronary
rtery surgery) or HF. The presence of clinical disease at
aseline was determined on the basis of the International
lassification of Diseases 9th Revision-Clinical Modifica-
ion (ICD9-CM) codes reported by Medicare and Medicaid
ervices for the years 1995 to 1998, self-reported history, and
he use of selected drugs, and ascertained by use of algorithms
irroring adjudicated diagnoses in the Cardiovascular
ealth Study (14). To assess the importance of diabetes,
imilar outcomes were assessed in the entire cohort stratified
y the presence or absence of diabetes. All comparisons were
one with chi-square test for categorical and t test for
ontinuous variables. The patients were divided into six
roups on the basis of the presence of zero to all five of the
etSyn risk factors in order to assess the importance of
ultiple MetSyn risk factors. Similar analyses were per-
ormed with chi-square test for trend.
Finally, we constructed a proportional hazard model (Cox
egression) to determine the adjusted likelihood of first
oronary death, first cardiovascular death, first any-cause
eath, first MI or MI death (other deaths censored), first
F hospital stay (all deaths censored), first CE (all death
ensored), or first any-cause hospital stay (all death cen-
ored) before six years (2,190 days) between two MetSyn
roups. Subjects who didn’t have events or who had events
hat happened six years after enrollment were censored.
otential confounders included in the regression were age,ace (white and black), gender (male and female), smoking
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April 18, 2006:1595–602 Metabolic Syndrome in Older Adultsnever, past, and current), marital status (married, widow,
nd other), site (Memphis and Pittsburgh), and the presence of
iabetes at baseline. We then chose clinically relevant interac-
ion terms to develop our model. This included the interaction
etween race and gender and the interaction between MetSyn
nd race. The effects of such interaction terms were tested
nd were found not to be statistically significant. They were
herefore not incorporated into the final model. Hazard
atio (HR) and 95% confidence interval (CI) were esti-
ated. Survival function plots were generated for first MI or
I death, first HF hospital stay, first CE, and first
ny-cause death. All analyses were done with PC-SAS
ersion 9.1 (SAS Institute, Inc., Cary, North Carolina).
ESULTS
tudy subjects. Table 1 describes the baseline characteris-
ics of the study population. Subjects with MetSyn were
ore likely to be women (57% vs. 48%, p  0.001),
idowed (33.1% vs. 29.4%, p 0.03), and white (60.7% vs.
7.0%, p  0.04). Common cardiovascular comorbidities
ssessed were all more prevalent among subjects with
etSyn (Table 1). The study population comprised primar-
ly moderate to high-risk individuals with only 6% of the
opulation with none of the five MetSyn risk factors.
utcomes. As shown in Table 2, patients with MetSyn
ere at a significantly higher risk of MI (9.1% vs. 5.7%), CE
19.9% vs. 12.9%), HF hospital stay (10.0% vs. 6.1%),
Table 1. Baseline Patient Characteristics
Characteristics
Overall Coh
(n  3,03
Age (yrs) 73.6
Gender (% men) 48.5
Race (% whites) 58.5
Smoking status (%)
Current 10.3
Past 45.9
Never 43.8
Marital status (%)
Married 54.8
Widowed 30.8
Other 14.4
Body mass index (kg/m2) 27.4
Systolic blood pressure (mm Hg) 135.8
Diastolic blood pressure (mm Hg) 71.4
Past medical history (%)
Coronary heart disease 23.1
Congestive heart failure 3.1
Diabetes 15.3
Hypertension 51.4
Metabolic syndrome criteria met (%)
HDL cholesterol 29.5
Triglycerides 30.7
Blood pressure 79.1
Fasting glucose 24.0
Waist circumference 61.0
Metabolic syndrome defined as presence of any of the three f
mg/dl for men and 50 mg/dl for women, triglycerides 150 mg/d
mg/dl, and waist circumference 102 cm (40 inches) for men any-cause hospital stay (63.1% vs. 56.1%) (all p values 
.001). The overall mortality was not different between the
wo groups (14.5% vs. 14.2%, p 0.85); however, there was
trend toward higher coronary mortality (4.5% vs. 3.2%,
 0.51) and cardiovascular mortality (5.1% vs. 3.8%, p 
.067) among patients with MetSyn. Higher risk for MI,
F hospital stay, and any-cause hospital stay was seen in
oth whites and blacks and in both genders.
When stratified by the presence of history of CHD or HF
t baseline, the risk for CE, MI, and HF hospital stay was
ignificantly higher among those with a positive past history
nd MetSyn at baseline. The overall event rates were lower
mong those with no past history of CHD or HF. Among
hese older adults also, the rate of CE was significantly
igher among subjects with MetSyn (14.5% vs. 9.1%, p 
.001). Yet the proportion of MI (6.1% vs. 4.8%, p  0.18)
nd HF hospital stay (5.6% vs. 4.3%, p  0.17), although
igher among those with MetSyn without past history of
HD or HF, did not reach statistical significance.
As shown in Table 3, patients with diabetes were at a
ignificantly higher risk of events irrespective of MetSyn
tatus; and among patients who did not have diabetes,
resence of MetSyn was associated with a higher risk for
E, MI, or HF hospital stay. Overall, presence of either
iabetes or MetSyn increased CE rate; subjects having
oth diabetes and MetSyn had higher risk compared with
ither alone.
Metabolic Syndrome
(n  1,169)
No Metabolic
Syndrome
(n  1,866) p
73.5 73.7 0.092
43.0 52.0 0.001
60.7 57.0 0.043
0.001
7.8 11.9
48.3 44.4
43.9 43.7
0.08
53.6 55.5
33.1 29.4
13.3 15.1
29.6 26.1 0.001
138.6 134.1 0.001
71.3 71.5 0.561
28.1 20.0 0.001
4.9 2.0 0.001
30.7 5.5 0.001
64.7 43.0 0.001
62.2 9.1 0.001
64.6 9.4 0.001
92.1 70.9 0.001
49.1 8.3 0.001
86.3 45.1 0.001
ng factors: high-density lipoprotein (HDL) cholesterol 40ort
5)
ollowi
l, blood pressure 130/85 mm Hg, fasting glucose 110
nd 88 cm (35 inches) for women.
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or overall mortality (13.4% vs. 9.0%, p  0.007), coronary
ortality (3.9% vs. 1.5%, p  0.002), and cardiovascular
ortality (4.4% vs. 1.9%, p  0.005) as compared with
hose without MetSyn. This relationship was not observed
mong men. Similarly, white subjects with MetSyn were at
higher risk for coronary mortality (4.2% vs. 2.5%, p 
.048) and had a trend toward higher cardiovascular mor-
ality (4.7% vs. 2.9%, p  0.06) as compared with those
ithout MetSyn.
Figure 1 shows the significance of MetSyn when the risks
re adjusted for age, gender, race, smoking, marital status,
Table 2. Associations Between Metabolic Synd
Outcomes
Meta
Entire cohort
Overall mortality (n  434)
Coronary mortality (n  112)
Cardiovascular mortality (n  130)
Myocardial infarction (n  213)
Heart failure hospital stay (n  231)
Coronary events (n  472)
Any-cause hospital stay (n  1,784)
Hospital stays per patient 1.6
Men (n  1,473)
Overall mortality (n  264)
Coronary mortality (n  73)
Cardiovascular mortality (n  84)
Myocardial infarction (n  140)
Heart failure hospital stay (n  121)
Coronary events (n  300)
Any-cause hospital stay (n  937)
Hospital stays per patient 1.8
Women (n  1,562)
Overall mortality (n  170)
Coronary mortality (n  39)
Cardiovascular mortality (n  46)
Myocardial infarction (n  73)
Heart failure hospital stay (n  110)
Coronary events (n  172)
Any-cause hospital stay (n  847)
Hospital stays per patient 1.5
White (n  1,774)
Overall mortality (n  221)
Coronary mortality (n  57)
Cardiovascular mortality (n  64)
Myocardial infarction (n  124)
Heart failure hospital stay (n  113)
Coronary events (n  278)
Any-cause hospital stay (n  1,028)
Hospital stays per patient 1.5
Black (n  1,261)
Overall mortality (n  213)
Coronary mortality (n  55)
Cardiovascular mortality (n  66)
Myocardial infarction (n  89)
Heart failure hospital stay (n  118)
Coronary events (n  194)
Any-cause hospital stay (n  756)
Hospital stays per patient 1.8nrollment site, and presence of diabetes. Coronary event fHR 1.56, 95% CI 1.28 to 1.91), MI (HR 1.51, 95% CI
.12 to 2.05), HF hospital stay (HR 1.49, 95% CI 1.10 to
.00), and any-cause hospital stay (HR 1.19, 95% CI 1.07 to
.32) were all significantly more common among patients
ith MetSyn even after adjusting for these factors. Figure 2
hows Kaplan-Meier curves for time to event-free sur-
ival among patients with and without MetSyn with
espect to MI, CE, HF, and any-cause hospital stay;
atients without MetSyn had longer event-free survival
or all end points.
ultiple risk factors. Table 4 shows the outcomes among
he entire cohort with respect to presence of multiple risk
e and Clinical Outcomes
Syndrome
1,169)
No Metabolic
Syndrome
(n  1,866) p
.5 14.2 0.850
.5 3.2 0.051
.1 3.8 0.067
.1 5.7 0.001
.0 6.1 0.001
.9 12.9 0.001
.1 56.1 0.001
5, 1.81) 1.29 (1.21, 1.38) 0.001
.9 19.0 0.15
.4 4.7 0.60
.2 5.5 0.58
.1 8.1 0.013
.1 6.2 0.001
.8 17.0 0.001
.8 62.0 0.07
4, 2.08) 1.40 (1.29, 1.52) 0.001
.4 9.0 0.007
.9 1.5 0.002
.4 1.9 0.005
.8 3.1 0.001
.4 6.0 0.07
.6 8.4 0.001
.2 49.8 0.001
9, 1.69) 1.17 (1.05, 1.29) 0.001
.0 12.1 0.60
.2 2.5 0.048
.7 2.9 0.06
.7 5.2 0.001
.7 4.8 0.001
.0 12.1 0.001
.6 55.6 0.01
2, 1.73) 1.19 (1.09, 1.28) 0.001
.8 17.0 0.93
.0 4.0 0.39
.9 4.9 0.43
.1 6.5 0.29
.0 7.9 0.02
.1 13.8 0.045
.4 56.9 0.003
3, 2.06) 1.43 (1.28, 1.58) 0.002rom
bolic
(n 
14
4
5
9
10
19
63
8 (1.5
15
5
6
12
12
26
66
6 (1.6
13
3
4
6
8
14
60
4 (1.3
13
4
4
9
8
21
61
7 (1.4
16
5
5
8
12
18
65actors, irrespective of MetSyn status. Except for all-cause
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ith increasing number of risk factors for coronary or
ardiovascular death, CE, MI, HF, and any-cause hos-
ital stay for patients with risk factors zero to five,
espectively.
ISCUSSION
etabolic syndrome, a common clinical problem with a
igh prevalence, has been associated with adverse cardio-
ascular risk and mortality in data consisting primarily of
iddle-aged populations with no special focus on older
dults (1–4,15). In this study we sought to assess the impact
f MetSyn on cardiovascular outcomes among older adults
nd found that it was associated was a significantly higher
igure 1. Overall effect of metabolic syndrome (MetSyn) on cardiovascu
onfidence intervals. Both unadjusted and covariate adjusted p values are s
Table 3. Metabolic Syndrome and Clinical Ou
Diabetes
.
Outcomes
Met
Patient with diabetes at baseline
Overall mortality (n  91)
Coronary mortality (n  31)
Cardiovascular mortality (n  37)
Myocardial infarction (n  52)
Heart failure hospital stay (n  59)
Coronary events (n  110)
Any-cause hospital stay (n  319)
Hospital stay per patient 2.
Patient without diabetes at baseline
Overall mortality (n  342)
Coronary mortality (n  81)
Cardiovascular mortality (n  93)
Myocardial infarction (n  160)
Heart failure hospital stay (n  171)
Coronary events (n  361)
Any-cause hospital stay (n  1,456)
Hospital stay per patient 1.male and female), smoking (never, past, and current), marital status (married,
iabetes at baseline.isk of CE, MI, HF hospital stay, all-cause hospital stay,
nd cardiovascular and coronary mortality among subjects
lder than 70 years. These associations were clearer in those
ith prevalent CHD or HF than those without. These
esults underscore the importance of aggressive treatment of
isk factors in older adults, because MI significantly impacts
n mortality, morbidity, and quality of life in these patients
16,17). Similarly, diabetes, impaired glucose tolerance, and
mpaired fasting glucose increase risk for cardiovascular events
18–20). The overall hospital stay rate was also substantially
igher among patients with MetSyn, confirming that patients
ith MetSyn are also at a higher risk for multiple other
iseases along with cardiovascular risk leading to worsening
utcomes and need for hospital stay.
utcomes and mortality. Point estimates of hazard ratios (HR) and 95%
. The covariates adjusted for included age, race (white and black), gender
es Stratified by Presence or Absence of
Syndrome
359)
No Metabolic
Syndrome
(n  102) p
8.1 25.5 0.10
6.4 7.8 0.61
7.5 9.8 0.45
1.1 11.8 0.86
3.4 10.8 0.49
5.9 16.7 0.053
1.9 59.8 0.02
86, 2.35) 1.82 (1.31, 2.34) 0.33
 809) (n  1,753)
2.9 13.6 0.62
3.7 2.9 0.28
4.1 3.4 0.41
8.2 5.4 0.01
8.5 5.8 0.01
7.2 12.7 0.002
9.1 55.8 0.12
34, 1.64) 1.18 (1.26, 1.35) 0.01lar o
howntcom
abolic
(n 
1
1
1
2
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10 (1.
(n
1
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5widow, and other), site (Memphis and Pittsburgh), and the presence of
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Metabolic Syndrome in Older Adults April 18, 2006:1595–602Our results also show a strong trend toward an increased
isk for coronary and cardiovascular mortality but not overall
ortality with MetSyn in older adults. This is in contrast to
he recent study in adult population in 30- to 74-year-old
ubjects that showed that MetSyn was not only associated
ith cardiovascular risk but also with overall mortality risk
4). There could be several reasons for this. In older adults,
eight loss is associated with elevated mortality risk. Be-
ause the MetSyn criteria are sensitive to weight change, it
ight be that participants without MetSyn include a sig-
ificant proportion of weight-losing subjects who also
igure 2. Adjusted survival curves for myocardial infarction (MI), heart fai
urvival plots adjusted for age, gender, race, smoking status, marital status
able 4. Cumulative Effect of Multiple Risk Factors on the Rate
Outcomes 0 (n  179) 1 (n  710)
verall mortality (%) 15.1 15.2
oronary mortality (%) 1.1 3.7
ardiovascular mortality (%) 1.7 4.1
yocardial infarction (%) 3.4 6.3
eart failure hospital stay (%) 1.7 5.6
oronary events (%) 6.7 13.7
ny-cause hospital stay (%) 53.1 56.1
ospital stays per patient (mean  SD) 1.11  0.24 1.31  0.13 1xperience a high mortality rate. There are competing risks
or mortality in older adults and therefore even if cardio-
ascular risk is attenuated, mortality reduction might be
ifficult to attain because other diseases (e.g., cancer) might
erminate life. Also, this is a 6-year follow-up study as
pposed to the study cited previously, which had a 13-year
ollow-up and higher proportion of events. Thus, further
ata are needed to assess the all-cause mortality relationship
ith MetSyn in older adults. Even if the main effect of
anaging MetSyn in older adults would be only a reduction
n cardiovascular morbidity, disability, and hospital stays,
CHF), coronary event, and overall hospital stay risk. The figures represent
and diabetes. Cum  cumulative; MetSyn  metabolic syndrome.
utcomes
umber of Risk Factors (%)
(n  977) 3 (n  659) 4 (n  387) 5 (n  123) p
13.3 12.8 15.5 20.3 0.61
3.2 4.0 3.9 9.8 0.01
3.9 4.6 4.7 9.8 0.01
5.7 7.7 9.3 15.5 0.001
7.3 8.4 11.4 14.6 0.001
13.4 16.5 22.2 30.1 0.001
56.7 60.4 64.1 74.0 0.001s of O
N
2.31  0.12 1.53  0.16 1.84  0.25 2.00  0.40 0.001
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f life.
The definition of MetSyn includes elevated fasting glu-
ose, which might be due to impaired fasting glucose or
iabetes. To assess the significance of MetSyn without
iabetes, we performed a sub-group analysis of patients with
nd without overt diabetes. Patients with diabetes were a
mall sub-group with a higher risk of events irrespective of
hether or not they met the criteria for MetSyn. This
ontrasts with data from the National Health and Nutrition
xamination Survey (NHANES)-III showing that MetSyn
odifies cardiovascular risk predictivity in diabetic subjects,
lthough this was a much larger, cross sectional study with
different age range (21). When patients with MetSyn
ithout diabetes were studied specifically in our study,
owever, the higher risk of CE, MI, HF, and any-cause
ospital stay was still evident. These results support both the
mportance of MetSyn irrespective of diabetes and the
verwhelming effect of diabetes on the vasculature in older
dults. Overall, presence of either diabetes or MetSyn
ncreased CE rate; subjects having both diabetes and
etSyn had higher risk compared with either alone.
We also assess the importance of MetSyn in both men
nd women and among whites versus blacks. Metabolic
yndrome was associated with worse outcomes in all four
acial and gender-based groups. An interesting observation
as that women seemed to have the strongest relationship
etween MetSyn and adverse outcomes, and theirs was the
nly sub-group where MetSyn was also associated with higher
ll-cause mortality (13.4% vs. 9.0%, p 0.007). Although one
hould be cautious in interpreting smaller subgroups with
ower event rates, these data are intriguing in light of recent
tudies delineating the gender differences with respect to
ardiovascular diseases and merit further investigation (22).
imilarly, white subjects as compared with black subjects
eemed to have a higher risk of coronary and cardiovascular
ortality in the presence of MetSyn.
We also assessed the importance of having multiple risk
actors irrespective of the presence or absence of MetSyn.
s shown in Table 4, there was a positive relationship with
orsening cardiovascular risk among older adults even when
ubjects had one or two risk factors but did not quality for
etSyn. These data would suggest that all risk factors
hould be managed aggressively. Table 4 also shows that
aving three elements of MetSyn does not maximize car-
iovascular risk, because outcome rates were highest among
ubjects with all five elements Further research is needed to
ssess the relative importance of one risk factor versus
nother and the impact of different combinations of risk
actors on outcomes.
There are several limitations to our study. The study
ncluded only well-functioning older adults, and therefore
he sicker and disabled subjects were excluded. The HF
utcomes studied were limited to HF hospital stays. Many
atients who might have developed HF might not haveequired a hospital stay. Similarly, we did not prospectively
ollect data on ejection fraction on all subjects. These data
nly represent the white and black races and might not be
eneralizable to other races. Finally, MetSyn was defined on
he basis of the ATP III original criteria, which included a
asting glucose of 110 mg/dl; however, this criteria has
ecently been changed to 100 mg/dl on the basis of
merican Diabetes Association/European Association for
he Study of Diabetes revised criteria for impaired fasting
lucose level (23). The impact of this change in the definition
f MetSyn in older adults needs further study.
In summary, our study shows that elderly subjects with
etSyn are at a higher risk for CE, MI, HF, and all-cause
ospital stay. Further studies are needed to assess the
easibility of risk factor modification and its impact on
utcomes in older adults. Age should not be a deterrent to
ggressive medical care.
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